Posts by Raymond J. March
Raymond J. March is a Research Fellow and Director of FDAReview.org with the Independent Institute. He is also an Assistant Professor of Economics at Angelo State University where he is the Assistant Director of the Free Market Institute, Assistant Research Professor at Texas Tech University, Public Choice and Public Policy fellow with the American Institute for Economic Research, and an affiliated scholar with the Challey Institute for Global Innovation and Growth. His research has appeared in Health Economics, Southern Economic Journal, Public Choice, Research Policy, Food Policy, Journal of Institutional Economics, The Independent Review and other academic outlets. His popular articles have appeared in Fortune, Washington Examiner, National Interest, Washington Times, Sun Sentinel, The Hill, Real Clear Health, Medical News Daily. He earned his Ph.D. from Texas Tech University.
If the FDA Wants People to Stop Smoking, it Should Stop Meddling in the Vaping Market
Supply, Demand, and Wegovy
What Would Kamala Harris’s FDA Look Like?
The Controversy Surrounding Microdosing Chocolate Bars
What is the future of psilocybin in medicine?
The FDA Is Coming After Microdosing Chocolate Bars
Why Are So Many Food and Beverage Products Being Recalled? 
The FDA Is Not a Referee
Will the Blundering FDA Receive More Power?
DEA and FDA Duke it Out Over Marijuana Scheduling
You Can’t Spend Your Way Out of an Opioid Crisis
Did Healthcare Spending Really Return to Pre-Pandemic Levels?
Another Infant Formula Shortage? Blame the FDA
Gene Therapy: A Promising Medical Frontier Hindered by Regulatory Roadblocks
Who Should Decide if Weight-Loss Injections Should be Prescribed for Kids?
More Oversight Won’t Help the US Baby Formula Market
The FDA Should Stay Away from Laboratory Developed Tests
The Pandemic is Over, But Pandemic Policies Are Not
FDA Efforts to Curb Youth Vaping Continue to Come Up Short
The FDA Loosens Blood Donation Restrictions, Finally
Recent Attacks on Recreational Marijuana Legalization Are All Smoke
Are Insulin Prices About to Drop? The Devil is in the Details
FDA’s Rare Positive Move
Insulin Price-Caps: A Solution or a Recipe for Rationing?
When is a Drug Safe and Effective Enough?
The FDA is Too Little Too Late in Tinkering with Covid-19 Booster Schedules

  • Catalyst
  • Beyond Homeless
  • MyGovCost.org
  • FDAReview.org
  • OnPower.org
  • elindependent.org